QT Imaging

About QT Imaging

QT Imaging Holdings, Inc. is a publicly-traded medical device company specializing in advanced body imaging systems that use low-frequency sound waves. The company was founded in 2011 by Dr. John C. Klock, who has served as the Chief Executive Officer since 2014. Dr. Klock has a background in founding multiple medical companies, including co-founding BioMarin Pharmaceutical.

The company's core product is the Breast Acoustic CT™ System (also known as QTscan®), an automated breast imaging system that provides 3D images without the use of compression or ionizing radiation. This technology is designed to offer a comfortable and safe patient experience, particularly for women with dense breasts or implants, where traditional mammography can be less effective. The system utilizes both transmission and reflection ultrasound to generate high-resolution, quantitative images that can characterize tissue based on the speed of sound. The company's business model involves the sale of these scanner systems to healthcare providers, such as hospitals and clinics. For the first quarter of 2025, QT Imaging reported shipping six scanners, generating $2.8 million in revenue.

QT Imaging has achieved significant milestones, including receiving over $15 million in grants from the National Institutes of Health (NIH) to support the technology's development. The U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the QTscan® to be used as an adjunct to mammography. In 2022, the FDA also provided clearance for the device to calculate the fibroglandular volume (FGV) of the breast, which aids in assessing breast cancer risk and treatment efficacy. The company is also developing an AI-enabled diagnostic platform to help radiologists differentiate between benign and malignant findings, with the goal of reducing false positives.